HAE Day supporters hope to end years of diagnostic uncertainty
Global efforts address barriers to diagnosis, treatment, and care
Written by |
Advocates around the world are preparing to mark May 16 as the day of awareness for hereditary angioedema (HAE), a rare genetic disorder that still takes an average of eight years to diagnose.
Since its inception in 2012, the annual observance known as “hae day :-)” has evolved into a vital platform for addressing systemic hurdles, such as diagnostic delays and unequal access to life-saving treatments.
“It is a time to connect, reflect, and stand united in support of people and families affected by HAE,” the US Hereditary Angioedema Association (HAEA) states on its website.
By uniting patients and researchers, the movement seeks to solve the significant challenges of living with HAE. These efforts are more than just symbolic; they drive the advocacy needed to ensure that geography and income do not dictate a patient’s health outcome.
Hereditary angioedema involves repeated episodes of swelling in the deeper layers of the skin and mucus membranes. This occurs due to the overproduction of bradykinin, a signaling molecule that makes blood vessels “leaky,” allowing fluids to seep into surrounding tissues.
Diagnostic delays and barriers to treatment
Despite medical advances, the rarity of HAE means that swelling episodes are frequently mistaken for common allergies. This confusion contributes to the long diagnostic delays cited by HAE International (HAEi), with many patients waiting years for answers. While symptoms may look like an allergic reaction, standard allergy medications are ineffective for HAE, which requires specialized treatments to target the underlying cause.
Advocates also use the awareness day to spotlight the high cost of care and limited access to first-line therapies. These issues disproportionately affect patients in rural and low-income communities in the U.S., as well as underrepresented racial and ethnic groups. For example, recent data suggest that while HAE affects all races equally, Black and Hispanic patients in the U.S. often face additional hurdles in accessing specialized immunology clinics compared to white patients.
Treatment access is a global issue, as large regions of Asia, Africa, Latin America, and Eastern Europe lack the diagnostic facilities or primary treatments necessary to manage the disease. Without these resources, many patients are forced to live without long-term prophylaxis, a preventive treatment that can stop swelling attacks before they start. The disorder affects about 1 in 50,000 to 150,000 people worldwide.
The community is fighting back through organizations like the HAEA. Through its Grassroots Advocacy Network, the nonprofit trains patients to urge policymakers and insurers to close gaps in care.
Network members, who are trained on how to be effective advocates, receive updates on policies affecting the HAE community, as well as advocacy alerts and newsletters. Focus areas include protecting and improving access to medications, increasing financial support for treatments, improving diagnosis times, and expanding federal funding for HAE research.
Currently, the HAEA is conducting a yearlong patient survey to capture lived experiences. This data will help doctors, insurers, and pharmaceutical companies set more effective standards of care.
On a global scale, HAEi serves as an umbrella organization for more than 100 patient associations. Founded in 2004, it offers resources like the Advocacy Academy, a suite of free online courses designed to help member organizations succeed in their local advocacy efforts.
